AU6914991A - Solubilization of t-pa - Google Patents

Solubilization of t-pa

Info

Publication number
AU6914991A
AU6914991A AU69149/91A AU6914991A AU6914991A AU 6914991 A AU6914991 A AU 6914991A AU 69149/91 A AU69149/91 A AU 69149/91A AU 6914991 A AU6914991 A AU 6914991A AU 6914991 A AU6914991 A AU 6914991A
Authority
AU
Australia
Prior art keywords
activity
acid
protein
solubilization
edta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU69149/91A
Other versions
AU625831B2 (en
Inventor
Ulrich Kohnert
Rudolph Rainer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of AU6914991A publication Critical patent/AU6914991A/en
Application granted granted Critical
Publication of AU625831B2 publication Critical patent/AU625831B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Lubricants (AREA)

Abstract

The invention relates to a pharmaceutical preparation of a protein with t-PA activity, with an enzymatic activity of at least 0.25 MU/ml and a pH of 4.5 to 9, containing a substance from the group citric acid, ascorbic acid, 2-oxoglutaric acid, fumaric acid, tris and EDTA in a concentration of at least 0.2 mol/l, and to a drug based on a protein with t-PA activity and a process for producing it.
AU69149/91A 1989-12-20 1990-12-19 Solubilization of t-pa Ceased AU625831B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3942145A DE3942145A1 (en) 1989-12-20 1989-12-20 T-PA SOLUBILIZATION
DE3942145 1989-12-22

Publications (2)

Publication Number Publication Date
AU6914991A true AU6914991A (en) 1991-07-18
AU625831B2 AU625831B2 (en) 1992-07-16

Family

ID=6395928

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69149/91A Ceased AU625831B2 (en) 1989-12-20 1990-12-19 Solubilization of t-pa

Country Status (11)

Country Link
EP (1) EP0458929B1 (en)
JP (1) JPH0657660B2 (en)
KR (1) KR920700683A (en)
AT (1) ATE102046T1 (en)
AU (1) AU625831B2 (en)
CA (1) CA2046598C (en)
DE (2) DE3942145A1 (en)
FI (1) FI95998C (en)
HU (2) HUT60133A (en)
NO (1) NO305582B1 (en)
WO (1) WO1991008764A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942141A1 (en) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2P PRO STABILIZATION
JP4601627B2 (en) 2004-01-16 2010-12-22 バイオデル， インコーポレイテッド Sublingual drug delivery device
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
GB8612868D0 (en) * 1986-05-27 1986-07-02 Mars G B Ltd Beverage packages
US4830853A (en) * 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3942142A1 (en) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh STABILIZATION OF GLYCOSYLATED T-PA

Also Published As

Publication number Publication date
CA2046598C (en) 1997-01-14
HU208630B (en) 1993-12-28
JPH0657660B2 (en) 1994-08-03
FI95998B (en) 1996-01-15
FI95998C (en) 1996-04-25
WO1991008764A1 (en) 1991-06-27
CA2046598A1 (en) 1991-06-21
KR920700683A (en) 1992-08-10
DE3942145A1 (en) 1991-06-27
ATE102046T1 (en) 1994-03-15
NO305582B1 (en) 1999-06-28
HUT60133A (en) 1992-08-28
DE59004814D1 (en) 1994-04-07
EP0458929A1 (en) 1991-12-04
EP0458929B1 (en) 1994-03-02
NO912775D0 (en) 1991-07-15
AU625831B2 (en) 1992-07-16
HU912740D0 (en) 1992-01-28
FI913907A0 (en) 1991-08-19
JPH04503680A (en) 1992-07-02
NO912775L (en) 1991-07-15

Similar Documents

Publication Publication Date Title
ZA96503B (en) Stable-lipid-comprising drug delivery complexes and methods for their production
LTIP1652A (en) Protein, biologically active hormone, method for protein production, pharmaceutical preparation
UA43348C2 (en) Aqueous pharmaceutical composition, which includes the factor of the nerve growth factor (variants) and liophilic pharmaceutical composition
DK0454898T3 (en) Glycosaminoglycan modified protein, method of producing the protein, pharmaceutical preparations containing the protein and use of the protein
AU6701890A (en) Process for the production of biologically active protein
DE3477137D1 (en) Aqueous solution containing lipid-soluble pharmaceutical substance and a process for preparing the same
EP0233013A3 (en) Modified enzyme
EG19583A (en) Process for preparing pharmaceutical composition from chymopapain
GR3004869T3 (en)
AU625831B2 (en) Solubilization of t-pa
ES8900018A1 (en) Rennin- and acid proteases-inhibitor peptidic amino alcohol derivatives, preparation process thereof and therapeutical application thereof.
CA2072797A1 (en) Use of tri (n-butyl) phosphate at low ph in solutions of biologically active proteins for enhanced virucidal activity
NO20003888L (en) Anti-enzyme preparations comprising ethylenediaminea succinic acid
HU912742D0 (en) T-pa pro-stabilization
NZ303133A (en) glycosylated human beta interferon
MY113432A (en) Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use for the production of pharmaceutical preparations, and medicaments containing them
AU6816787A (en) (Gem-heterocyclodimethanamine-N,N') platinum complexes
ES8406425A1 (en) Galenic form of amitriptyloxide, and process for its preparation.
IE880198L (en) Plasminogen activator.
Kohnert et al. Stabilized compositions having human tissue type plasminogen activator enzymatic activity
ATE41418T1 (en) S-(CARBAMOYL-PHENYLSELENYL) DERIVATIVES OF GLUTATHIONE AND AMINOMERCAPTOCARBONIC ACIDS, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
RU95111293A (en) METHOD OF THERAPY OF ACUTE PNEUMONIA